ArticleInternational ophthalmology2020
Risk factors associated with avascular fibrous membrane in patients with retinopathy of prematurity.
Article in International ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe sought to assess the risk factors associated with avascular fibrous membrane development in patients with retinopathy of prematurity (ROP).
methodsThis retrospective, cross-sectional study included premature infants diagnosed with ROP. Gestational age, birth weight, stage and zone of the ROP, the presence of plus disease, and laser photocoagulation (LP) application were noted for each patient. Location, extension, development time, vanishing time of the avascular fibrous membrane, and associated complications were also noted. Patients who developed avascular fibrous membrane formed the membrane group (n = 38) and those who did not develop avascular fibrous membrane formed the control group (n = 208).
resultsMean gestational age and birth weight did not differ between the groups (p = 0.897 and p = 0.343). ROP developed significantly earlier in the control group than in the membrane group (p < 0.001). The patients in the control group underwent LP treatment significantly earlier than did patients in the membrane group (p < 0.001). Regression analysis showed that higher postmenstrual age at the time of ROP diagnosis increased the risk of avascular fibrous membrane development by up to 1.6-fold (p = 0.002; 95% CI 1.2-2.3) and later LP treatment was associated with a 3.3-fold increased risk of avascular fibrous membrane development (p = 0.003; 95% CI 1.5-7.3).
conclusionsLate-onset ROP and later LP treatment were found to be associated with an increased risk of avascular fibrous membrane development in patients with ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.